Electrochemotherapy in 3D Ocular Melanoma Spheroids using a Customized Electrode

Summary

Here, we present a protocol for the development of 3D conjunctival and uveal melanoma spheroids and the use of hand-held customized electrodes for in vitro electrochemotherapy of 3D spheroids in a culture well. This offers new perspectives in the use of electrochemotherapy in ocular melanoma treatment.

Abstract

Electrochemotherapy (ECT) is the combination of transient pore formation following electric pulse application with the administration of cytotoxic drugs, which enhances the cytotoxic effect of the applied agent due to membrane changes. In vitro 3D culture systems simulate the in vivo tumor growth and preserve the biological characteristics of tumors more accurately than conventional monolayer cell cultures. We describe a protocol for the development of 3D tumor organoids using conjunctival melanoma (CM) and uveal melanoma (UM) cell lines as well as the use of hand-held customized electrodes, suitable for in vitro ECT in the culture well without destruction of the tumor environment. This protocol analyzes the culture and growth of 3D CM and UM spheroids and their reaction to bleomycin (2.5 µg/mL) alone, electroporation (EP) (750 Volts/cm, 8 pulses, 100 µs, 5 Hz) alone, and ECT as a combination of EP and bleomycin. The drug concentration and the EP settings used in this protocol were established as preferred ECT conditions according to previous experiments. The assay used to determine the spheroid viability was conducted 3-7 days following treatment. The effect on viability and growth of the 3D tumor spheroids was significant only after ECT. The customized electrodes are described in detail in order to facilitate the application of pulses in the culture well. This novel treatment of 3D UM and CM spheroids sets a steppingstone for future clinical application.

Introduction

Uveal melanoma (UM) is the most common primary intraocular tumor in adults, whereas conjunctival melanoma (CM) represents 2% of all ocular melanomas^1,2,3,4,5,6. Brachytherapy, proton beam radiotherapy, and phototherapy are the first line treatments in UM, whereas enucleation of the globe may be necessary^1,2,3. The treatment of CM varies between ocular oncology centers; excisional biopsy followed by local chemotherapy and/or radiation therapy is the most frequent treatment approach⁴. Despite treatment, CM is associated with a mortality of 25%–30%⁵.

There is a paucity of literature on the formation of CM and UM spheroids and the application of ECT in ocular melanoma^6,7,8. Tumor spheroids have better biological features than conventional 2D cell cultures and have been proposed as a useful tool to mimic the in vivo tumor environment⁹. Electrochemotherapy (ECT) combines the use of non-permeable cytotoxic drugs with electroporation (EP)¹⁰. EP is the local application of short and intense electric pulses that transiently permeabilizes cells for a localized increase of anti-cancer drug uptake in cancer cells and results in increased cell death¹¹. This study establishes a protocol describing the development of CM and UM spheroids and investigates the results following ECT with bleomycin. This protocol could assist investigators in the field of ocular oncology using other therapeutic modalities on spheroids or study further effects of ECT. Due to the limited use of ECT in ophthalmology, there is little knowledge regarding the effect and process of this modality; thus, this experiment may widen the spectrum of treatment options in the future. We propose a novel customized hand-held plate electrode setting, which allows the ECT of the spheroid in the culture wells without any destruction of the tumor environment.

Protocol

1. Spheroid formation

1. Use adherently growing cancer cell lines for spheroid formation.
2. Provide all cell culture associated steps under sterile bench conditions.
3. Prepare the standard complete culture medium as recommended for the cell lines of interest and warm to 37 °C using a water bath.
   NOTE: Here, the human conjunctival cell lines CM2005.1, CRMM1, CRMM2 as well as the uveal melanoma cell lines 92.1, OMM1and OMM2 were used and cultured in Ham F-12 medium containing 10% fetal bovine serum and RPMI containing 10% fetal bovine serum, respectively.
4. Detach the cells of interest using standard enzymatic digestion methods (e.g., trypsin-EDTA solution).
5. To determine the number of vital cells, resuspend 10 µL of the cell suspension in 10 µL of Trypan blue solution (1:1) and count the cells using a chamber (hemocytometer or an automated cell counter) within 5 min. Cells should be <90% of confluence and in good condition.
6. To form spheroids, seed 5 x 10³ cells per well with a total volume of 200 µL of complete culture medium in 96-well ultra-low attachment plates. Incubate the plate at 37 °C in a humidified atmosphere containing 5% CO₂.
   NOTE: For effective inhibition of cellular attachment, use ultra-low attachment plates with a covalently bound hydrophilic, non-ionic, neutrally charged hydrogel on the surface. This hydrogel inhibits immortalization of cells and force them into a suspended state to build 3D spheroids.
7. Check the spheroid formation using a microscope.
   NOTE: Some cell lines do not form round 3D tumor spheroids in the first passage. Passage the tumor sphere culture before they start to develop a dark center. Dissociate the tumor masses depending on the cell line after 4-10 days by trypsinization. Afterwards, seed the single cells in a fresh 96 ultra-low attachment plate. By repeating this procedure for several passages, cells will adapt to 3D culture.

2. Electrochemotherapy of the tumor spheroids

1. As an assay control, use untreated spheroids and spheroids treated only with EP or bleomycin alone.
2. Adjust the settings for the electroporator (pulse counts, pulse frequency, duration time and voltage; see Table of Materials). For melanoma cells, use 8 square wave electric pulses of 750 Volts/cm strength, 100 µs pulse duration, 5 Hz repetition frequency.
3. At day 3 of spheroid culture, prepare fresh bleomycin sulfate solution in sterile PBS at a concentration of 5 µg/mL in a 15 mL tube.
4. Exchange the cell culture medium of the spheroids by removing 200 µL of culture medium and refilling with 100 µL of fresh complete culture medium for each well.
5. Add 100 µL of bleomycin sulfate solution to each well (final concentration 2.5 µg/mL). Add 100 µL of fresh medium to untreated controls and spheroids only treated with EP instead of bleomycin sulfate solution.
6. Perform the electroporation.
   NOTE: The electrodes shown in Figure 1 were produced in the research workshop of the University of Halle-Wittenberg. They are made of stainless steel and fit the grip of the electroporator. The electrodes were designed for use in 96 well ultra-low attachment plates. Similar stainless-steel electrodes can be easily manufactured for alternative applications too.
   1. Sterilize electrodes with 70% ethanol and allow electrodes to dry. The diameter of the electrodes is 1 mm, the gap between the two electrodes is 4 mm, and the length of each electrode is 8 mm (Figure 1a).
   2. Place the electrodes at the bottom of the well, with the spheroids between the electrodes. This allows the ideal positioning of the spheroid between the two electrodes (Figure 1b).
   3. Shake the plate to allow the spheroids to move from the bottom of the well and be placed between the electrodes. The spheroid will only be between the electrodes for a couple of seconds.
   4. Start the electroporation with preferred settings.
   5. Replace the bleomycin sulfate solution in the well by exchanging 150 µL of medium with 150 µL of fresh medium.
   6. Incubate the cells for up to 10 days at 37 °C in a humidified atmosphere containing 5% CO₂. If the untreated spheroids start to develop a dark center, terminate the experiment. Exchange 150 µL of the cell culture medium every 2-3 days. Thereby, avoid spheroid disruption by positioning the pipette tip at the edge region of the well, tilting the plate and slowly pipetting.

3. Determination of spheroid size

1. Measure the spheroid size on the day of treatment (starting point) and 3-7 days following treatment using bright field microscopy by calculating the cross sectional area of the spheroids using ImageJ Fiji¹¹.
2. Take an image of the single spheroids with the scale bar. Use a magnification by which the whole spheroid is visible. For example, 5x magnification was used for CM2005.1. Save the image as a JPEG.
3. Analyze the spheroid size by calculating the cross-sectional area using ImageJ/Fiji.
   1. Install the software (https://imagej.net/Fiji/Downloads).
   2. Start ImageJ/Fiji. Import the spheroid-image: File > Open.
   3. To set the scale, choose the line button of the toolbar and mark the line of the scale bar in the image by mouse click: Analyze > Set Scale. Using a known distance, fill in the distance of the scale bar. Change the Unit of length to µm. Click the field global to assign the settings for all images with the same magnification factor.
   4. Convert the image to 8-bit: Image > Type > 8-bit.
   5. Choose Image > Adjust > Auto Threshold (Select > Do not reset range). The spheroid is marked in red or black depending on the threshold marker chosen. Adjust the sliders so that the spheroid pixels turn red, but non-spheroid pixels do not change color. Close the Threshold dialog window without clicking any of the buttons.
   6. To calculate the cross-sectional area of the spheroid, choose Analyze > Set Measurements and click Area, Limit to Threshold and Display label. Close the Set Measurements dialog window by clicking OK.
   7. To show the results, choose Analyze > Analyze Particles and change the size (µm²) = 10000-infinity to remove noise. Click the button Display results and close the window by clicking OK. In the Results, the spheroids with the label and area are shown. By repeating the analyses of several spheroids, the results are listed in the Results window.
   8. To determine the relative treatment response of the ECT treated spheroids compared to the untreated and single treated controls, calculate the percentage changes of the cross-sectional area.

4. Determination of spheroid viability

1. Measure the spheroid viability 3-7 days following treatment using a cell viability assay suitable for 3D cell cultures according to the manufacturer instructions. The assay needs to penetrate and lyse large spheroids to allow detection of viability by quantitation of ATP, which signals the presence of metabolically active cells.
   NOTE: In this experiment, a luminescence-based assay as a readout method was used. The viability of the ECT-treated spheroids was compared to controls seven days following treatment.

Discussion

EP is used in various biotechnological and clinical applications¹². New technological developments, such as specially designed electrodes with high specificity for every target cell and site, may help ECT target tissue anywhere in the body¹². The design and position of the electrodes must allow complete tumor accessibility and ensure that healthy tissue is only minimally affected or not damaged from the treatment¹³.

Previous publications showed the effect of ECT in human melanoma cell suspensions in vitro^7,8. The literature referring to the application of ECT in 3D ocular cell models or other similar in vivo environments, enabling a safer therapeutic utilization, is limited. Brun et al. postulate that the 3D cells in the scaffold during the morphological analysis have a round shape different from the elongated shape shown in the 2D cultures but extremely similar to the cells from biopsies of patients⁹. The refinement of therapy settings and instruments used in 3D cultures may lead to an optimization of ECT parameters, allowing a more accurate clinical approach⁹.

We describe a technological development regarding new electrodes for the application of ECT in 3D cell cultures. Bleomycin is the most commonly administered cytotoxic agent in combination with ECT¹¹. Previous studies of our group showed that the applied EP settings (750 Volts/cm, 8 pulses, 100 ms, 5 Hz) were suitable for treatment of ocular tumors in vitro. Critical steps of the technique include the short time needed to perform the ECT while the spheroid is sinking after mobilization as well as the precise dimension of the electrodes. The necessity for the customized electrodes was due to difficulties in performing ECT in the wells with the available instruments. Unpublished data from our group showed increased spheroid damage when transferring the spheroids into a bigger well or into a cuvette to prepare them for treatment and then back to the culture well. An advantage of the described technique is the lack of spheroid manipulation to perform the treatment, because the organoids are not transferred into bigger plates or wells. Therefore, all spheroids retain their form. Another advantage is the use of more robust 3D viability assays to determine cytotoxicity of ECT compared to standard viability assays, such as the MTT assay. Thereby, all cells of the spheroid are lysed and additional cell washing, removal of medium and multiple pipetting steps are required.

Limitations of the described methods are the short lifespan of spheroids, which affects the size of the tumor as well as the cell necrosis, as seen in the center of the tumor organoid. The associated high mortality rate in both CM and UM and the limited therapeutic options require the enrichment of the existing therapeutic possibilities. ECT may offer an adjuvant modality for the improvement of the patient’s quality of life and prolong the patient’s survival. These in vitro conditions imitate an in vivo setting with higher precision, offering promising results for further human application. Future studies using spheroids prepared from primary cultures can deliver more representative results for optimization of ECT settings for a targeted treatment.

Materials

Name	Company	Catalog Number	Comments
Bleomycin sulfate	Enzo	BML-AP302-0010	10 mg
Cell culture flask 75 cm	TPP	TPP90076
Cell culture flask TC175 cm	Sarstedt	83,39,12,002	Standard with Filter
Cliniporator	IGEA	EPS01	Electroporator
Corning Costar Ultra-Low Attachment Multiple Well Plate, 96 well, round bottom	Corning	7007	96Well clear round Bottom, Ultra low attachment plates
EGF 1MG	Sigma-Aldrich	E4127-.1MG
F-12 K Nut Mix (1x)	Gibco	21127-022
Fetal Bovine Serum, South American	Corning	35-079-CV	LOT Nr. 35079010, Reservierungsnummer: EU00478541
FKS
KGM-2	Lonza	CC-3103
PBS w/o. CaCl und MgCl	PromoCell	C-40232	500 ml
Penicillin-Streptomycin	Sigma-Aldrich	P4333-100ml
RPMI 1640	Gibco	11504566	ATCC modification, HEPES, liquid, 500 ml
Tecan Infinity M Plex	Tecan
Trypsin-EDTA 1x Solution	Sigma-Aldrich	59430C-100ml